KLRA logo

KLRA Kailera Therapeutics, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$11.02
-0.56 (-4.84%)

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral s…

Market Cap: $1.43Bwww.kailera.com

Price

No data yet.

Social Signal Score

50
5d
—
30d
50
3 mentions
—
60d
50
4 mentions
—
90d
50
5 mentions
—
news: 5

Analyst Ratings

Avg price target$42+281.1%
Low $36Median $42High $48
Current Consensus

Revenue

$0.00
$0.00
Dec 31Sep 30

Analyst Estimates

FY2025
$-7819.98
$-7819.98–$-7819.98
2 analysts
FY2026
$-3.92
$-4.71–$-3.13
4 analysts
FY2027
$-3.86
$-4.55–$-2.91
5 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Ronald C. Renaud Jr.
Sector
Healthcare
Industry
Biotechnology
Employees
145
Beta
0.50
Country
US
www.kailera.com